

William S Denney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5152633/publications.pdf>

Version: 2024-02-01

27
papers

1,316
citations

489802

18
h-index

591227

27
g-index

27
all docs

27
docs citations

27
times ranked

2078
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 533-543.	0.6	1
2	Safety and pharmacodynamics of an engineered <i>E. coli</i> Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. <i>Nature Metabolism</i> , 2021, 3, 1125-1132.	5.1	72
3	Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria. <i>Communications Biology</i> , 2021, 4, 898.	2.0	10
4	Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. <i>American Journal of Gastroenterology</i> , 2020, 115, 783-785.	0.2	27
5	AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. <i>Cell Reports Medicine</i> , 2020, 1, 100057.	3.3	72
6	<sc>SBML</sc> Level 3: an extensible format for the exchange and reuse of biological models. <i>Molecular Systems Biology</i> , 2020, 16, e9110.	3.2	178
7	Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs. <i>European Journal of Pain</i> , 2019, 23, 1129-1140.	1.4	12
8	An engineered <i>E. coli</i> Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	242
9	Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. <i>Blood</i> , 2019, 134, 1090-1090.	0.6	11
10	Translational Development of Microbiome-Based Therapeutics: Kinetics of <i>E. coli</i> Nissle and Engineered Strains in Humans and Nonhuman Primates. <i>Clinical and Translational Science</i> , 2018, 11, 200-207.	1.5	24
11	Pharmacokinetics and pharmacodynamics of PF05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 326-338.	1.1	40
12	Cardiovascular Safety Assessment in Early-Phase Clinical Studies: A Meta-Analytical Comparison of Exposure-Response Models. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 324-335.	1.3	5
13	Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active-Controlled Study. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 517-527.	0.8	17
14	Two dose-ranging studies with PF04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 751-759.	2.2	38
15	Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 831-837.	1.1	20
16	A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations. <i>Blood</i> , 2015, 126, 3502-3502.	0.6	1
17	A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design. <i>AAPS Journal</i> , 2014, 16, 1259-1270.	2.2	14
18	An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 581-598.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1926-1939.	1.7	18
20	Pharmacokinetics and Pharmacodynamics of MK-046, a Bombesin Receptor Subtype-3 (BR3) Agonist, in Healthy Patients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1306-1316.	1.0	33
21	Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 15-22.	1.1	79
22	Systems Biology of Coagulation Initiation: Kinetics of Thrombin Generation in Resting and Activated Human Blood. <i>PLoS Computational Biology</i> , 2010, 6, e1000950.	1.5	125
23	Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. <i>Xenobiotica</i> , 2009, 39, 637-648.	0.5	21
24	Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow. <i>Blood</i> , 2008, 111, 3507-3513.	0.6	111
25	Functional phenotyping of human plasma using a 361-fluorogenic substrate biosensing microarray. <i>Biotechnology and Bioengineering</i> , 2006, 94, 1099-1110.	1.7	32
26	Stochastic Modeling of Blood Coagulation Initiation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 80-90.	0.5	52
27	Neutrophil-Bead Collision Assay: Pharmacologically Induced Changes in Membrane Mechanics Regulate the PSGL-1/P-Selectin Adhesion Lifetime. <i>Biophysical Journal</i> , 2005, 89, 3603-3614.	0.2	32